PTO/SB/08A (10-96) ough 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of

Complete if Known				
Application Number	10/024,036			
Filing Date	December 17, 2001			
First Named Inventor	Rajasekhar Bandaru			
Group Art Unit	1652			
Examiner Name	David J. Steadman			
Attorney Docket Number	MPI00-521P1RM			
Altorney Docket Number	MP100-521P1RM			

			U.S.	PATENT DOCUM	ENTS	
Examiner Initials*	Cite No.1	U.S. Patent Document Kind Code <sup>2</sup> Number (if known)	Name of P	atentee or Applicant ted Document	Date of Publicati Cited Docume (MM-DD-YYY	ent Relevant Passages or Relevant
DIS	A1	5,885,803 A	Incyte Phar	maceuticals, Inc.	03/23/1999	Entire document
			FOREIG	ON PATENT DOCU	MENTS	
Examiner	Cite	Foreign Patent Do	cument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where

Examiner	Cite	Fore	ign Patent Do	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where	
Initials*	No.¹	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	or Applicant of Cited Document	Cited Document (MM-DD-YYYY)	Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1						150	)
	ļ						CENT	
							DEUL	_
		<del></del>					3003	3_
							IUN 1 7 CO	
							-ra 16	Ø
							TECH CENTER	
							TEUI	

Examiner Signature	Date Considered	8-14-03
--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation design number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

e through 10/31/99. OMB 0654-0031 Approved T

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for form 1449B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary) of

Complete if Known					
Application Number	10/024,036				
Filing Date	December 17, 2001				
First Named Inventor	Rajasekhar Bandaru				
Group Art Unit	1652				
Examiner Name	David J. Steadman				
Attorney Docket Number	MPI00-521P1RM				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	C1	VERPLOEGEN, S., et al. "Identification and Characterization of CKLiK: A Novel Granulocyte Ca2+/Calmodulin-Dependent Kinase" Database Submitted July 11, 2000, Dept. Pulmonary Diseases, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.	
DIS		EMBL-EBI Accession No. AF286366	
D.C.	C2	STRAUSBERG, ROBERT, March 14, 2000. Alignment of Al923704 and SEQ ID NO: 1 show 612 contiguous nucleotide matches. National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <a href="http://www.ncbi.nlm.nih.gov/nciegap">http://www.ncbi.nlm.nih.gov/nciegap</a>	
DIS	-	EMBL-EBI Accession No. Al923704	
	ļ	-WED	
		SECEIVE	
		PL 2 2003	
		JUN , AUL	10/50
	:	RECEIVED JUN 1 2 2003 TECH CENTER 16	
		1EO.	

Examiner Signature Date Considered 8-14-03
--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.





<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here is English language Translation is attached.